Form 4: Celldex Therapeutics SVP and CFO Martin Samuel Bates Reports Stock Transactions

Martin Samuel Bates, SVP and CFO of Celldex Therapeutics, exercised stock options and sold shares on May 30, 2024.

Summary

• On May 30, 2024, Martin Samuel Bates, the SVP and CFO of Celldex Therapeutics, exercised incentive stock options to acquire 25,000 shares of common stock at a price of $10.38 per share.
• Simultaneously, Bates sold 35,000 shares of common stock at a weighted average price of $34.0507 per share, with individual sales ranging from $33.69 to $34.55.
• Following these transactions, Bates directly owns 25,128 shares of Celldex Therapeutics common stock and holds options for 80,600 shares.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard disclosure of insider trading activity. The CFO exercised options and sold shares, which could be for various personal financial reasons and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock sale may have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.

Key Dates